Trial Profile
A Randomised, Parallel Group, Placebo-controlled, Double Blind Study to Assess the Safety and Tolerability of SB-681323 at 7.5mg Daily Dose for 28 Days and Its Effect on the Levels of Serum C-reactive Protein (CRP) in Subjects With Rheumatoid Arthritis (RA)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Dilmapimod (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 30 May 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 13 Jan 2012 Actual patient number is 78 according to ClinicalTrials.gov.
- 13 Jan 2012 Actual end date (Oct 2006) added as reported by ClinicalTrials.gov.